enGene (ENGN) announced that the FDA has selected detalimogene voraplasmid to participate in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program. Detalimogene is a novel, investigational, non-viral gene therapy for patients with high-risk, non-muscle invasive bladder cancer.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- enGene to Present at Piper Sandler Healthcare Conference
- enGene Holdings Closes $130 Million Public Offering
- enGene 12.559M share Spot Secondary priced at $8.50
- enGene Holdings Prices $130 Million Public Offering to Advance Genetic Medicine Programs
- enGene Holdings Announces Public Offering of Common Shares